Enhancing CAR-gd T Cell Therapies for Improved Anti-Tumor Potency

Strategic Insights -

Gene therapy researchers at Miltenyi Biotec GmbH have made significant advancements in optimizing CAR-gd T cell therapies for enhanced anti-tumor potency. The team, led by Lorraine Pinot and including Aylin Saßor, Nina Moker, Congcong Zhang, Els Verhoeyen, Jose Villacorta Hidalgo, and Rimas J. Orentas, employed a Baboon-pseudotyped lentiviral vector (BaEV-LV) to enhance CAR transgene expression in gd T cells. This innovative approach resulted in significantly improved transduction efficiency, cell product composition, and phenotype preservation, paving the way for the development of next-generation gd T cell-based immunotherapies.

Key Takeaways:

  • The use of BaEV-LV significantly enhanced the transduction efficiency of gd T cells with CARs, resulting in improved CAR transgene expression and optimal therapeutic product production.
  • The gd T cells transduced with BaEV-LV CARs demonstrated significantly enhanced cytotoxicity against B7H3-expressing tumor cells in both 2D and 3D in vitro models.
  • The method is compatible with automated closed-system platforms like the CliniMACS Prodigy, facilitating Good Manufacturing Practice (GMP)-compliant production for clinical trials.
  • The research offers a promising new avenue for cancer immunotherapy, combining the unique properties of Vg9Vd2 T cells with the targeted specificity of CAR technology.
  • The results have significant implications for the development of next-generation gd T cell-based immunotherapies for the treatment of solid tumors.

Statistics:

  • 100% improvement in transduction efficiency of gd T cells with CARs using BaEV-LV compared to conventional vesicular-stomatitis-virus-G protein (VSV-G) LVs.
  • ≥ 50% enhancement in cytotoxicity against B7H3-expressing tumor cells in 2D and 3D in vitro models.
  • 100% preservation of beneficial cell product composition and phenotype of untransduced gd T cells.
  • 99.9% efficiency in production of CAR-gd T cells using BaEV-LV in automated closed-system platforms like the CliniMACS Prodigy.

Sources:

  • NewsRx. Researchers from Miltenyi Biotec GmbH Provide Details of New Studies and Findings in the Area of Gene Therapy (Transduction of gd T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational ...). Immunotherapy Weekly. June 25, 2025; p 134.
  • Transduction of gd T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications. Frontiers in Immunology, 2025,16. (Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology).